Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
Authors:
- Monica M ReinholzMRMonica M Reinholz
- Amy K BruzekABAmy K Bruzek
- Daniel W VisscherDVDaniel W Visscher
- Wilma L LingleWLWilma L Lingle
- Matthew J SchroederMSMatthew J Schroeder
- Edith A PerezEPEdith A Perez
- Robert B JenkinsRJRobert B Jenkins
- 1 March 2009
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (3) , 267-277
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17European Journal of Cancer, 2007
- The effect of chromosome 17 polysomy on HER-2/neu status in breast cancerJournal of Clinical Pathology, 2007
- Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancerBreast Cancer Research and Treatment, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- Using array-comparative genomic hybridization to define molecular portraits of primary breast cancersOncogene, 2006
- Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study1Journal of the American College of Surgeons, 2000
- Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationLaboratory Investigation, 2000
- Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sectionsBreast Cancer Research and Treatment, 1996
- Cytogenetics of breast cancerCancer Genetics and Cytogenetics, 1990